Claire Harrison, MD, details the implications of the INDEPENDENCE trial data for luspatercept in myelofibrosis-associated anemia.
Claire Harrison, MD
Advertisement
Articles by Claire Harrison, MD
Claire Harrison, MD, discusses data for luspatercept in myelofibrosis-associated anemia from the INDEPENDENCE trial.
Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).
Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.
Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.
Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Harrison on the Current State of Treatment in MyelofibrosisDecember 1st 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5